MedImmune Aktie
WKN DE: 881824 / ISIN: US5846991025
03.04.2018 08:31:30
|
AstraZeneca: FDA Grants Moxetumomab Pasudotox BLA Priority Review
(RTTNews) - AstraZeneca and MedImmune, its global biologics research and development arm, announced the US FDA has accepted the Biologics License Application (BLA) for moxetumomab pasudotox, an investigational anti-CD22 recombinant immunotoxin and a potential new medicine for the treatment of adult patients with hairy cell leukaemia who have received at least two prior lines of therapy.
The FDA has granted the moxetumomab pasudotox BLA Priority Review status with a Prescription Drug User Fee Act date set for the third quarter of 2018.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu MedImmune Inc.mehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu AstraZeneca PLC (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
AstraZeneca PLC (spons. ADRs) | 67,00 | 0,75% |
|